# Obesity-Hypoventilation Syndrome

Confirm awake hypercapnia in an obese patient, exclude alternative causes of hypoventilation, identify coexisting sleep-disordered breathing, and use positive-airway-pressure therapy to prevent recurrent acute-on-chronic hypercapnic respiratory failure.

**Clinical question:** How should physicians confirm, phenotype, and manage obesity-hypoventilation syndrome in stable and acutely hypercapnic adults?

Updated: 2026-08-24T16:12:47.770664+00:00

## What matters in practice
- Diagnose OHS only when obesity with BMI at least 30 kg/m² coexists with awake arterial hypercapnia, PaCO2 greater than 45 mm Hg, after other causes of hypoventilation have been excluded. [7][11][23]
- Obtain an arterial blood gas to document daytime hypercapnia; a serum bicarbonate threshold of 27 mmol/L is used to identify patients who warrant confirmatory arterial blood-gas assessment. [10]
- Do not assume hypercapnia is due solely to obstructive sleep apnea: approximately 10% of patients with OHS do not have obstructive sleep apnea, and hypoxemia or daytime hypercapnia may persist despite CPAP elimination of obstructive events. [16]
- Treat confirmed OHS with positive-airway-pressure therapy; CPAP and noninvasive ventilation are both initial-treatment strategies, while NIV is an effective treatment for OHS with chronic respiratory failure. [3][20]
- Hospitalized or sedated patients require heightened vigilance for acute ventilatory deterioration; opioids can cause respiratory depression and should be used with extreme caution in patients with sleep apnea, severe obesity, hypoxia, hypercapnia, or pre-existing respiratory depression. [1]

## Identify acute-on-chronic ventilatory failure before outpatient phenotyping

Escalate care when an obese patient has altered mentation, hypoxemia, or known or suspected hypercapnia.

OHS is associated with hospitalizations for acute-on-chronic hypercapnic respiratory failure and with chronic heart failure and pulmonary hypertension. In a patient with severe obesity and suspected ventilatory failure, obtain an arterial blood gas promptly to establish PaCO2 and PaO2, then determine whether the presentation represents previously unrecognized chronic hypercapnia or acute deterioration on chronic respiratory failure. [23]

Review immediately reversible ventilatory depressants. Opioids, including transdermal buprenorphine, can dangerously decrease pulmonary ventilation, especially when combined with other respiratory depressants. Risk is amplified by severe obesity, sleep apnea, hypoxia, hypercapnia, COPD or cor pulmonale, and pre-existing respiratory depression; profound sedation, unresponsiveness, infrequent deep breaths, atypical snoring, and respiratory distress are warning findings. [1]

Use noninvasive ventilatory support when OHS is accompanied by chronic respiratory failure or when acute hypercapnic decompensation requires ventilatory assistance; NIV is an effective treatment modality in OHS. Once stabilized, transition to a formal sleep-disordered-breathing and daytime gas-exchange assessment rather than labeling the patient as having isolated obstructive sleep apnea. [3][23]
- Obtain arterial blood gas testing when hypercapnia is suspected; PaCO2 greater than 45 mm Hg fulfills the awake hypercapnia component of OHS. [7][11][23]
- Reconcile opioids and other respiratory depressants before administering additional sedating medication in a patient with hypercapnia or sleep apnea. [1]
- Treat recurrent or persistent ventilatory failure as an indication to evaluate long-term positive-airway-pressure requirements rather than relying on oxygenation measures alone. [3][16]

*Findings that should redirect immediate evaluation in suspected obesity-related hypoventilation. [1][23]*

| Clinical finding | Interpretation | Next action |
| --- | --- | --- |
| Obesity with altered mental status, hypoxemia, or respiratory distress | Possible acute-on-chronic hypercapnic respiratory failure. [23] | Obtain arterial blood gas and assess need for noninvasive ventilatory support. [3][23] |
| Profound sedation, unresponsiveness, infrequent deep breaths, or atypical snoring after opioid exposure | Possible opioid-induced respiratory depression. [1] | Stop further respiratory depressants and urgently assess ventilation and oxygenation. [1] |
| Persistent daytime hypercapnia after obstructive events are controlled on CPAP | Suggests a ventilatory disorder beyond obstructive-event elimination. [16] | Reassess positive-airway-pressure strategy and consider NIV. [3][16] |

## Confirm OHS with awake arterial hypercapnia and exclusion of competing causes

The diagnosis requires an arterial daytime measurement, not nocturnal symptoms or obesity alone.

Establish OHS when all three elements are present: BMI at least 30 kg/m², awake PaCO2 greater than 45 mm Hg, and no alternative pathology that explains hypoventilation. The threshold is expressed as PaCO2 at least 45 mm Hg in consensus definitions and greater than 45 mm Hg in other diagnostic descriptions; clinically, a daytime PaCO2 of 45 mm Hg or higher should trigger assessment for OHS when obesity is present. [7][11][23]

Use serum bicarbonate as a screening discriminator rather than a diagnostic substitute. A bicarbonate threshold of 27 mmol/L is used to select patients for arterial blood-gas analysis; confirm suspected OHS with an ABG because the syndrome is defined by awake arterial hypercapnia. [10][11]

Do not diagnose OHS until alternate causes of hypoventilation have been considered. The defining exclusion is other pathology causing hypoventilation; specifically assess whether COPD or another chronic lung disorder, neuromuscular or chest-wall disease, medication-related CNS depression, or another cause better accounts for daytime CO2 retention. Severe obesity, sleep apnea, hypoxia, hypercapnia, CNS depression, and clinically significant kyphoscoliosis can coexist and increase vulnerability to respiratory depression, but coexistence does not eliminate the need to determine the dominant cause of hypoventilation. [1][11][23]
- BMI at least 30 kg/m² plus awake PaCO2 at least 45 mm Hg establishes the physiologic core of OHS only after exclusion of another explanatory disorder. [7][11][23]
- If serum bicarbonate is at least 27 mmol/L in a patient being evaluated for sleep-disordered breathing, obtain an ABG to assess PaCO2. [10]
- Document daytime arterial hypercapnia before assigning long-term OHS-directed ventilatory therapy. [11][23]

*Diagnostic branching for obesity and suspected daytime hypoventilation. [7][10][11][23]*

| Branch point | Finding | Interpretation and next step |
| --- | --- | --- |
| Body habitus | BMI at least 30 kg/m². [7][11][23] | OHS is possible; proceed to assessment of daytime PaCO2. [7][11] |
| Screening chemistry | Serum bicarbonate at least 27 mmol/L. [10] | Obtain arterial blood gas for confirmatory PaCO2 measurement. [10] |
| Arterial blood gas | Awake PaCO2 at least 45 mm Hg or greater than 45 mm Hg. [7][11][23] | Meets the hypercapnia criterion; evaluate exclusion diagnoses and sleep-disordered breathing. [11][23] |
| Alternative explanation | Another pathology explains hypoventilation. [11][23] | Do not classify as isolated OHS; manage the identified cause and assess the contribution of obesity or sleep-disordered breathing. [11][23] |

## Define the relationship between OHS and obstructive sleep apnea

Sleep-disordered breathing is common but does not fully explain every OHS phenotype.

Perform formal assessment for sleep-disordered breathing after confirming or strongly suspecting obesity-related daytime hypercapnia. OHS is defined in contemporary descriptions by obesity, awake hypercapnia, absence of alternate causes, and sleep-disordered breathing; however, about 10% of patients with OHS do not have obstructive sleep apnea. [16][23]

When obstructive sleep apnea is present, use positive-airway-pressure titration to eliminate apneas and hypopneas. CPAP titration in OHS has been directed at eliminating obstructive respiratory events, but response must include reassessment of nocturnal oxygenation and daytime gas exchange because approximately 40% of patients with OHS have persistent nocturnal hypoxemia and daytime hypercapnia after CPAP eliminates sleep apnea. [16][19]

Persistent hypercapnia or hypoxemia after adequate obstruction control is a management branch, not simply a reason to raise CPAP pressure. It indicates that contributors other than upper-airway obstruction remain clinically relevant and supports reassessment for noninvasive ventilation. [3][16]
- Confirm whether obstructive sleep apnea is present before selecting CPAP as an obstruction-focused strategy. [16][19]
- After CPAP eliminates apneas and hypopneas, reassess daytime PaCO2 and nocturnal oxygenation rather than assuming ventilatory correction. [16][19]
- If gas-exchange abnormalities persist despite control of obstructive events, reconsider NIV and re-evaluate competing causes of hypoventilation. [3][16]

*Sleep-disordered-breathing patterns that alter the next treatment decision in OHS. [3][16][19]*

| Observed pattern | Clinical implication | Next step |
| --- | --- | --- |
| OHS with obstructive events eliminated during CPAP titration. [19] | CPAP addresses upper-airway obstruction. [19] | Check whether nocturnal hypoxemia and daytime hypercapnia resolve. [16] |
| Persistent hypoxemia or daytime hypercapnia after CPAP eliminates sleep apnea. [16] | Nonobstructive contributors to hypoventilation remain important. [16] | Reassess ventilatory support and consider NIV. [3][16] |
| OHS without obstructive sleep apnea. [16] | An obstruction-focused CPAP rationale is absent. [16] | Assess ventilatory support requirements with NIV-centered management. [3][16] |

## Select CPAP or noninvasive ventilation according to the gas-exchange response

Positive-airway-pressure treatment is central; the mode should match obstructive-event burden and ventilatory failure.

Use positive-airway-pressure treatment in confirmed OHS. Randomized trials have compared CPAP with NIV as initial therapy, and NIV is an effective treatment for OHS with chronic respiratory failure. The practical distinction is whether CPAP eliminates the clinically relevant obstructive component while restoring gas exchange, versus whether ongoing hypoventilation requires pressure support ventilation. [3][20]

Select CPAP when obstructive sleep apnea is the dominant treatable sleep finding and use titration directed at eliminating apneas and hypopneas. Do not equate successful event control with successful OHS treatment: persistent nocturnal hypoxemia or daytime hypercapnia after CPAP is documented in about 40% of affected patients and should prompt a switch in the clinical question from airway patency to ventilation. [16][19]

Use NIV when chronic respiratory failure is present, when obstructive sleep apnea is absent, or when CPAP adequately controls obstructive events but gas exchange remains abnormal. Published trials include pressure-support and volume-targeted approaches, but NIV titration may be suboptimal if sleep transcutaneous CO2 is not used; therefore, pair device follow-up with objective CO2 and oxygenation reassessment when available. [3][16][21][24]

Avoid iatrogenic ventilatory suppression during long-term management. Opioids can produce respiratory depression, and the labeling specifically identifies sleep apnea, severe obesity, hypoxia, hypercapnia, COPD or cor pulmonale, and CNS depression as high-risk states. Before escalating sedatives or opioids, verify the patient’s current ventilatory status and PAP adherence. [1]
- CPAP target during titration: eliminate apneas and hypopneas. [19]
- NIV indication: OHS with chronic respiratory failure or persistent gas-exchange failure despite obstruction control. [3][16]
- Follow treatment response with objective daytime PaCO2 and assessment of nocturnal oxygenation; sleep transcutaneous CO2 can inform NIV titration. [16][21]
- Review opioid exposure at each treatment change because respiratory depression risk is increased by hypercapnia, sleep apnea, severe obesity, and hypoxia. [1]

### Weight-loss interventions

Weight loss may improve sleep-disordered breathing in severe obesity. In a small postoperative series in which all patients underwent Roux-en-Y surgery, repeat oximetry at 12 months showed resolution or improvement of oxygen desaturation in most reassessed patients who had used CPAP preoperatively. This observation supports reassessment after substantial weight loss but does not justify stopping CPAP or NIV without repeat physiologic testing. [4]
- After substantial post-bariatric weight loss, repeat sleep-related oxygenation assessment before discontinuing CPAP or NIV. [4]

*Positive-airway-pressure selection and follow-up in OHS. [3][16][19][20][21]*

| Treatment branch | Treatment target | Objective reassessment |
| --- | --- | --- |
| OHS with obstructive sleep apnea responsive to CPAP titration | Eliminate apneas and hypopneas with CPAP. [19] | Recheck daytime PaCO2 and nocturnal oxygenation because gas-exchange abnormalities may persist. [16] |
| OHS with chronic respiratory failure | Use NIV as ventilatory support. [3] | Assess CO2 and oxygenation response; transcutaneous CO2 can inform sleep NIV titration. [21] |
| Persistent hypercapnia or hypoxemia after CPAP controls obstructive events | Treat residual hypoventilation rather than simply increasing obstruction-focused CPAP. [16] | Reassess for NIV and alternative contributors to hypoventilation. [3][16] |
| Substantial weight loss after bariatric surgery | Do not presume resolution of sleep-disordered breathing. [4] | Repeat physiologic assessment before withdrawing PAP therapy. [4] |

## Monitor ventilation, not only symptoms or obstructive-event control

The follow-up endpoint is corrected gas exchange with sustained treatment use.

At follow-up, compare daytime PaCO2 with the pretreatment ABG and assess nocturnal oxygenation after PAP initiation or adjustment. This is essential because OHS can retain daytime hypercapnia and nocturnal hypoxemia after CPAP has eliminated obstructive sleep apnea. [16][19]

Use sleep transcutaneous CO2, when available, to guide NIV optimization because absent transcutaneous CO2-based titration has been identified as a potential source of suboptimal NIV titration. Persistent CO2 elevation despite apparent device success should trigger review of delivered ventilation, adherence, sleep-disordered-breathing phenotype, opioid or sedative exposure, and competing causes of hypoventilation. [1][21]

Reassess after major clinical change, including acute hypercapnic hospitalization, increased opioid exposure, or substantial weight loss. OHS is associated with recurrent acute-on-chronic hypercapnic respiratory failure, while postoperative improvement in sleep-related oxygen desaturation after Roux-en-Y weight loss does not establish that ventilatory support can be withdrawn without repeat testing. [4][23]
- Track daytime PaCO2 after initiation or escalation of PAP therapy. [16][19]
- Assess nocturnal oxygenation after CPAP or NIV changes. [16]
- Use transcutaneous CO2 during sleep NIV titration when available. [21]
- Repeat objective testing before stopping PAP after marked weight loss. [4]

*Follow-up triggers that warrant repeat physiologic assessment. [1][4][16][21][23]*

| Trigger | Why it changes management | Assessment |
| --- | --- | --- |
| CPAP eliminates obstructive events but daytime hypercapnia persists | Residual hypoventilation may require NIV. [16] | Repeat ABG and nocturnal oxygenation assessment; reassess ventilatory strategy. [3][16] |
| NIV adjustment or inadequate clinical response | Ventilation may be insufficient despite treatment use. [21] | Use nocturnal transcutaneous CO2 when available and reassess gas exchange. [21] |
| New opioid or sedative exposure | Respiratory depression risk rises with sleep apnea, obesity, hypoxia, and hypercapnia. [1] | Review medication exposure and assess ventilation promptly if sedation or respiratory symptoms occur. [1] |
| Substantial postoperative weight loss | Sleep-related oxygen desaturation may improve or resolve, but individual response requires confirmation. [4] | Repeat sleep-related physiologic testing before reducing or stopping PAP. [4] |

## References
1. CENTER FOR DRUG EVALUATION AND ... - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306Orig1s000Lbl.pdf
2. Pediatric Obstructive Sleep Apnea Syndrome — jamanetwork.com — https://jamanetwork.com/journals/jamapediatrics/fullarticle/486098
3. Non-invasive ventilation in obesity hypoventilation ... — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/early/2016/07/12/thoraxjnl-2016-208501.full.pdf
4. Poster Presentations — thorax.bmj.com — https://thorax.bmj.com/content/62/Suppl_3/A64
5. Oxygen therapy in COPD — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/62/Suppl_3/A64.full.pdf
6. Abstracts - 2013 - Sleep and Biological Rhythms — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/sbr.12028
7. International Consensus Statement on Obstructive Sleep ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/alr.23079
8. Non‐invasive ventilation for obese patients with chronic respiratory failure: Are two pressures always better than one? — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/resp.13588
9. Obesity Hypoventilation Syndrome (OHS) as A Chronic ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.72991
10. Sleep disordered breathing assessment in patient with ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/am/pii/S1389945724000091
11. Obesity hypoventilation syndrome — journals.lww.com — https://journals.lww.com/aotm/_layouts/15/oaks.journals/downloadpdf.aspx?an=01284540-200904020-00002
12. Gender differences in patients starting long-term home ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0954611115300913
13. Hypoxic burden and sleep hypoventilation in obese patients — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1389945724004295
14. How do I wean a patient with acute hypercapnic respiratory ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2531043722001787
15. American Journal of Respiratory and Critical Care Medicine — www.atsjournals.org — https://www.atsjournals.org/doi/abs/10.1164/rccm.201905-1071ST
16. Noninvasive positive pressure ventilation for stable ... — www.ccjm.org — https://www.ccjm.org/content/ccjom/77/10/705.full.pdf
17. National Occupational Research Agenda (NORA) — www.cdc.gov — https://www.cdc.gov/niosh/docket/review/docket302/pdfs/302-Final-NORA-Agenda-for-Respiratory-Health-12-20-18.pdf
18. Surgery for weight loss in adults - Colquitt, JL - 2014 — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003641.pub4/references/po
19. Positive Airway Pressure Titration in Obesity Hypoventilation ... — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(15)37488-2/fulltext
20. Obesity Hypoventilation Syndrome : Chest — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(15)00127-0/pdf
21. Long-term Noninvasive Ventilation in Obesity Hypoventilation ... — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(20)30711-X/fulltext
22. Patients With Hypoventilation Syndromes - Chest Journal — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(21)01484-7/abstract
23. Study Details | NCT07147153 | Functional Capacity, Sleep Quality, and Cognitive Function in Obesity Hypoventilation Syndrome | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT07147153
24. Study Details | NCT06047405 | NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06047405

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.